Daniel A. Pollyea, MD

Daniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.

Daniel Pollyea, MD, MS, discusses improving induction outcomes for newly diagnosed patients with acute myeloid leukemia.

Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.